# A Single Dose Study to Assess the Regional Absorption and Bioavailability of 100mg GSK2190915A

> **NCT01318980** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 14 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** GSK2190915 100mg milled tablet
- **DRUG:** [14C] radiolabelled GSK2190915 solution
- **DRUG:** GSK2190915 100mg milled tablet administered to the proximal small bowel.
- **DRUG:** GSK2190915 100mg milled tablet administered to the distal small bowel.
- **DRUG:** GSK2190915 100mg enteric-coated tablet.

## Key facts

- **NCT ID:** NCT01318980
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-09-30
- **Primary completion:** 2011-03-11
- **Final completion:** 2011-03-11
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2017-08-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01318980

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01318980, "A Single Dose Study to Assess the Regional Absorption and Bioavailability of 100mg GSK2190915A". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01318980. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*